How long until I see results from AOD-9604?

Acute effects from AOD-9604 appear within hours of dosing for receptor-level changes. anabolic and recovery endpoints accumulate across 4–8 weeks; the typical 8–12 week cycle is calibrated to allow the full response window. Single-week evaluations consistently underestimate the response trajectory.

What are the safety considerations for AOD-9604?

No significant elevation of IGF-1, glucose, or insulin in trials. Generally well tolerated. Pregnancy/lactation: avoid (no data). For anabolic and recovery use, additional considerations: baseline labs appropriate to the targeted system, mid-cycle re-check at 4–6 weeks, and end-of-cycle full re-evaluation. AOD-9604's ~30 min IV; longer SubQ pharmacokinetic profile and subq/oral (capsule, lower bioavailability) administration route influence the side-effect profile in predictable ways.

What does AOD-9604 stack well with?

For body composition / training protocols, AOD-9604 pairs with compounds on complementary pathways: IGF-1 LR3, CJC-1295 + Ipamorelin Blend, TB-500. These pairings are selected because they engage independent receptor systems from AOD-9604's primary mechanism (Mimics the C-terminal of human growth hormone (residues 176-191) to stimulate lipolysis and inhibit lipogenesis via β3-adrenergic-like signalling, without engaging the GH receptor or driving IGF-1 elevation), producing additive or synergistic effects rather than receptor competition.

What route should I use for AOD-9604?

AOD-9604 is delivered by subq/oral (capsule, lower bioavailability). Subcutaneous administration is standard for ${o.cat.toLowerCase()} class peptides and provides reliable systemic bioavailability. The choice depends on target system and convenience.

What is the standard dosing protocol for AOD-9604?

Conventional AOD-9604 dosing is 300-500 mcg 1x daily am via subq/oral (capsule, lower bioavailability). For anabolic and recovery use specifically, the cycle pattern is typically 8–12 weeks on followed by a 4 week off-period. Higher doses are studied in advanced protocols but produce diminishing dose-response in the published literature.

Home/ Compounds/ AOD-9604

AOD-9604

Body Composition

For the body-composition and physique community, AOD-9604 is run inside a training-driven framework where the compound supports rather than substitutes for stimulus and nutrition. Mimics the C-terminal of human growth hormone (residues 176-191) to stimulate lipolysis and inhibit lipogenesis via β3-adrenergic-like signalling, without engaging the GH receptor or driving IGF-1 elevation. The ~30 min IV; longer SubQ pharmacokinetic profile determines training-day versus rest-day dosing, while the subq/oral (capsule, lower bioavailability) administration shapes injection-site rotation and protocol planning.

Body Composition / Training Applications

Muscle EnduranceCardiovascular ConditioningTendon RepairRecoveryInjury Recovery

Key Takeaways

Body composition lens: response to AOD-9604 is proportional to training stimulus and nutritional adequacy.
Mechanism: Mimics the C-terminal of human growth hormone (residues 176-191) to stimulate lipolysis and inhibit lipogenesis via β3-adrenergic-like signalling, without engaging the GH receptor or driving IGF-1 elevation.
Body composition dose: 300-500 mcg 1x daily am via subq/oral (capsule, lower bioavailability); effects visible at week 4-8 with adequate training and protein.
Cycle structure: 8-12 weeks on, 4 weeks off; training-day or daily dosing depending on half-life.
Performance stack partners: IGF-1 LR3, CJC-1295 + Ipamorelin Blend, TB-500.

Body Composition / Training Mechanism

For trained users, AOD-9604's body composition response is generated at the intersection of compound pharmacology, training stimulus, and nutritional input. Mimics the C-terminal of human growth hormone (residues 176-191) to stimulate lipolysis and inhibit lipogenesis via β3-adrenergic-like signalling, without engaging the GH receptor or driving IGF-1 elevation. The mechanism informs which training and nutrition pattern maximises the response; the subsections below work through this for the four dimensions tracked in body composition protocols.

Anabolic substrate and protein synthesis

AOD-9604's relevance to body composition depends on where in the anabolic cascade it acts. It engages the GH/IGF-1 axis directly, with measurable effects on protein synthesis, satellite cell activation, and lean mass over a typical 8–12 week cycle. The downstream effect on body composition is dose- and training-dependent.

Hyperplasia and structural adaptation

Where AOD-9604 demonstrates effects on fibre count rather than fibre size — hyperplasia rather than hypertrophy — the structural adaptation matters more than the acute anabolic signal. Most peptides in this category contribute to the hypertrophic rather than hyperplastic adaptation, with the magnitude depending on training stimulus.

Training-day versus rest-day dosing

Many peptides in this category respond better to training-day-only versus rest-day-included dosing. AOD-9604 with a ~30 min IV; longer SubQ half-life of ~30 min IV; longer SubQ is short-lived enough that timing relative to training sessions matters. The practical dosing schedule reflects this.

Body Composition / Training Applications

Anabolic Support

The body composition community converges on AOD-9604 for anabolic support with reported best-fit cycles of 8–12 weeks. Off-cycle of 4 weeks is standard. Stacking with complementary peptides on different pathways is the typical pattern for advanced users.

Training Performance

For training performance, AOD-9604 integrates with training programming on a per-session and per-cycle basis. Training-day dosing produces stronger acute effect; rest-day inclusion supports sustained baseline. The protocol pattern reflects training intensity and recovery demand.

Lean Mass

Lean Mass responds to AOD-9604 with effect sizes proportional to training stimulus and nutritional adequacy. Users running aggressive caloric deficits see reduced response; users in surplus with adequate protein see proportionally larger response. Programming the inputs is half the protocol.

Endurance

The body composition community converges on AOD-9604 for endurance with reported best-fit cycles of 8–12 weeks. Off-cycle of 4 weeks is standard. Stacking with complementary peptides on different pathways is the typical pattern for advanced users.

Dosing Protocol

Goal	Route	Dose	Cycle
Standard protocol	SubQ	300-500 mcg	8–12 weeks on / 4 weeks off
Conservative starter	SubQ	180-500 mcg	4–6 weeks initial cycle
Body Composition focus	SubQ	300-500 mcg	1x daily AM
Maintenance phase	SubQ	210-500 mcg	Ongoing with periodic pauses

Dose timing for AOD-9604 is important relative to food and training given the short half-life. Consistency through the cycle is more important than the precise clock time of individual doses. Fasted dosing produces stronger GH pulses; meal-paired dosing blunts the response.

Stacking

AOD-9604 stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from performance coaches and athletes.

AOD-9604 + IGF-1 LR3: Binds the IGF-1 receptor with full agonist activity. Pairs naturally with AOD-9604's mechanism in body composition / training protocols.
AOD-9604 + CJC-1295 + Ipamorelin Blend: CJC-1295 stimulates the GHRH receptor; ipamorelin stimulates the ghrelin/GHSR receptor. Pairs naturally with AOD-9604's mechanism in body composition / training protocols.
AOD-9604 + TB-500: Binds G-actin monomers and prevents their incorporation into F-actin filaments, regulating the cellular actin pool. Pairs naturally with AOD-9604's mechanism in body composition / training protocols.
AOD-9604 + BPC-157: Upregulates VEGFR2 to promote angiogenesis and activates the FAK-paxillin pathway for accelerated tissue repair. Pairs naturally with AOD-9604's mechanism in body composition / training protocols.

Safety & Regulatory Status

WADA: Not on prohibited list (verify annually) FDA: Unapproved (Research Only) Research: Phase IIb completed; not commercialised

No significant elevation of IGF-1, glucose, or insulin in trials. Generally well tolerated. Pregnancy/lactation: avoid (no data).

Lens-specific safety considerations for body composition / training use of AOD-9604: No significant elevation of IGF-1, glucose, or insulin in trials. Generally well tolerated. Pregnancy/lactation: avoid (no data). Additional body composition / training monitoring at baseline and 6–8 week follow-up is appropriate.

Clinical Evidence

Primary

Effects of an oral lipolytic peptide (AOD9604) on body composition in obese subjects

PMID 12972433

Supporting

AOD9604 and obesity: clinical findings

PMID 19077115

AOD-9604 vs Related Peptides

Compound	Profile	Onset	Best For
AOD-9604	GH fragment	~30 min IV; longer SubQ	Body Composition
IGF-1 LR3	Modified insulin-like growth factor 1	~20-30 hr (vs ~10 min for native IGF-1)	A modified IGF-1 with a 13-amino-acid N-terminal extension and Arg substitution that resists IGFBP binding — extending half-life from 10 minutes to roughly a day
Tesamorelin	Stabilised GHRH analogue	~30 min	An FDA-approved long-chain GHRH analogue used for HIV-associated lipodystrophy and notable for its consistent effect on visceral adipose reduction
Ipamorelin	Selective GHRP / ghrelin mimetic	~2 hr	The most selective ghrelin-receptor agonist among the GHRPs — stimulates GH release with minimal effect on cortisol, prolactin, or appetite

Frequently Asked Questions

Can I use AOD-9604 alongside creatine, protein, and standard supplements?

Yes — peptide protocols are fully compatible with the standard supplement stack. Creatine, protein powder, beta-alanine, citrulline, and the like operate on entirely separate mechanisms and are additive. Pre-workout stimulants and high-caffeine intake are also compatible.

How does AOD-9604 compare to AAS for body composition?

Peptide therapeutics including AOD-9604 produce more modest body composition shifts than anabolic-androgenic steroids and operate on different mechanisms with substantially different side-effect profiles. The compound is most-appropriate for users prioritising long-term sustainability and clean blood work over maximum acute mass.

Best stack pairing for lean mass?

The canonical lean mass stack pairs AOD-9604 with a complementary GH-axis component, a connective-tissue support peptide, and — in advanced protocols — an anabolic-supportive component. Specific pairings depend on which dimension of body composition is prioritised: pure mass, mass-and-fat-loss, or recovery-focused.

Training-day only or daily dosing?

For most peptide compounds with short-to-moderate half-life, training-day dosing produces stronger acute effect; rest-day inclusion supports sustained baseline. The choice depends on the user's training volume and the compound's pharmacokinetics. Daily dosing for 4-7 days is the default; training-day-only protocols are appropriate for lower-volume programmes.

Is AOD-9604 safe during pregnancy or breastfeeding?

AOD-9604, like most non-approved peptide therapeutics, does not have safety data supporting use during pregnancy or lactation. The default position is contraindication during pregnancy, lactation, and active conception, with discontinuation at least 2–3 cycles before planned conception. Approved indications (where they exist) may have specific guidance — verify with the prescribing physician.

Should I cycle AOD-9604?

Standard cycle for AOD-9604 is 8–12 weeks of 1x daily am 300-500 mcg dosing via subq/oral (capsule, lower bioavailability), followed by a 4 week complete off-period. The off-period is calibrated to AOD-9604's ~30 min IV; longer SubQ half-life and to typical receptor downregulation timelines. Continuous indefinite dosing does not show additional clinical benefit in the published literature and increases cumulative downregulation risk.

Clinical Protocol

Start a AOD-9604 Protocol

Alukard provides physician-supervised body composition protocols with GMP-certified AOD-9604 and GMP-certified compounds and training-aware dosing guidance.

Get Protocol

Quick Facts

Molecular weight: 1815.1 Da
Sequence length: 16 aa
Half-life: ~30 min IV; longer SubQ
WADA: Not on prohibited list (verify annually)
FDA: Unapproved (Research Only)
Research: Phase IIb completed; not commercialised

Stack Partners

IGF-1 LR3

CJC-1295 + Ipamorelin Blend

TB-500

BPC-157

Tesamorelin + Ipamorelin Blend

Research Note

All body composition / training applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for AOD-9604 unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.

Physician-supervised body composition protocols

Start Your Body Composition / Training Protocol for AOD-9604

Alukard provides physician-supervised body composition protocols with GMP-certified compounds and training-aware dosing guidance.

Get a Physician Consultation View All Compounds

HIPAA Compliant · GMP Certified · Physician Supervised